本文来源:时代财经 作者:张羽岐图片来源:图虫创意3月27日晚间,港股18A药企华领医药(02552.HK)发布2024年全年业绩。财报显示,受核心产品多格列艾汀(商品名:华堂宁)销售影响,2024年华领医药销售收入持续增加,至2.56亿元,同比上年增加234%。这一年华堂宁共销售约为211万盒,销售遍布中国内地约2700家医院,而上年同期华堂宁卖出25.1万盒。不过,华领医药仍处于亏损阶段,其...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.